GSK plc (NYSE: GSK) has announced that it has received marketing approval from the European Commission (EC) for its Menveo vaccine, a Meningococcal Group A, C, W-135, and Y conjugate vaccine (MenACWY vaccine), in a single-vial, fully liquid presentation. This formulation is designed for the prevention of invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W, and Y.
Convenience and Efficacy in a Single-Vial Presentation
The newly approved single-vial presentation offers a convenient option for active immunization of children from 2 years of age, adolescents, and adults, eliminating the need for reconstitution before use. This advancement in vaccine presentation is expected to enhance the ease of administration and potentially increase vaccination rates across the approved age groups.
Market Comparison and Availability
The product is not yet approved in China, where a similar product, CanSino Biologics’ Menhycia, is commercially available. This highlights the potential market opportunity for GSK’s Menveo vaccine in China and other regions where meningococcal vaccines are in demand.-Fineline Info & Tech
